Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
 
Sign in
Join now
story of the week
Published in COVID-19 and
2 other channels

Journal Scan / Research · August 11, 2020

Immunogenicity and Safety of a Recombinant Adenovirus Type-5-Vectored COVID-19 Vaccine in Healthy Adults

The Lancet

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Jonathan Temte MD, PhD

Jonathan Temte MD, PhD

The Lancet
Immunogenicity and Safety of a Recombinant Adenovirus Type-5-Vectored COVID-19 Vaccine in Healthy Adults Aged 18 Years or Older: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
Lancet 2020 Jul 20;[EPub Ahead of Print], F-C Zhu, X-H Guan, Y-H Li, J-Y Huang, T Jiang, L-H Hou, J-X Li, B-F Yang, L Wang, W-J Wang, S-P Wu, Z Wang, X-H Wu, J-J Xu, Z Zhang, S-Y Jia, B-S Wang, Y Hu, J-J Liu, J Zhang, X-A Qian, Q Li, H-X Pan, H-D Jiang, P Deng, J-B Gou, X-W Wang, X-H Wang, W Chen

Further Reading

Most Read This Week

Recently Updated